Mar 21, 2023
David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components...
Mar 21, 2023
David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components...
Feb 28, 2023
Dr. Robert Risinger is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. ...
Feb 28, 2023
Dr. Robert Risinger is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. ...
Oct 4, 2022
Stan Abel is the Chief Executive Officer of ProJenX, working on developing therapeutics to get into the brain to access the motor neurons that are dying in ALS and other brain and neurological diseases. Their drug prosetin is optimized to be bioavailable and administered in a small amount of liquid which is an advantage...